These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 321684)

  • 1. Activity of tumor-associated lymphoid cells at short intervals after administration of irradiated syngeneic and allogeneic tumor cells.
    Schick B; Berke G
    J Immunol; 1977 Mar; 118(3):986-91. PubMed ID: 321684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-associated lymphoid cells: analysis of host cells that bind to syngeneic and allogeneic tumor cells shortly after tumor administration.
    Schick B; Berke B
    Transplant Proc; 1977 Mar; 9(1):1157-60. PubMed ID: 867485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differing contribution of various effector cells in the elimination of syngeneic or allogeneic cells.
    Matsumoto T; Himeno K; Mitani M; Mori K; Miake S; Nomoto K
    J Clin Lab Immunol; 1986 Feb; 19(2):83-9. PubMed ID: 3083105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies of the mechanisms for the induction of in vivo tumor immunity. IV. Enhancement of the in vitro generation of secondary cell-mediated cytotoxic response by normal peritoneal macrophages and their culture supernatants.
    Igarashi T; Rodrigues D; Ting CC
    J Immunol; 1979 Apr; 122(4):1519-27. PubMed ID: 156217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies of H-2 restriction in cell-mediated cytotoxicity and transplantation immunity to Leukemia-associated antigens.
    Ting CC; Law LW
    J Immunol; 1977 Apr; 118(4):1259-64. PubMed ID: 191534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
    Cohen P; Vourka-Karussis U; Weiss L; Slavin S
    J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
    Fuyama S; Yamamoto H; Fujii Y; Arai S
    Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
    Uharek L; Glass B; Zeis M; Dreger P; Steinmann J; Löffler H; Schmitz N
    Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
    Sensi M; Orosz CG; Bach FH
    J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral regulation of cell-mediated immunity to syngeneic tumor.
    Ting CC
    Cancer Res; 1976 Oct; 36(10):3695-701. PubMed ID: 953995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
    Weiss L; Reich S; Slavin S
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tryptophan degradation in transplanted tumor cells undergoing rejection.
    Yoshida R; Park SW; Yasui H; Takikawa O
    J Immunol; 1988 Oct; 141(8):2819-23. PubMed ID: 3262668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
    Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
    Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophage tumoricidal activity as a possible antitumor mechanism associated with the local injection of allogeneic spleen cells into rats.
    Kawase I; Komuta K; Namba M; Yokota S; Ogura T; Kishimoto S
    Cancer Res; 1986 Mar; 46(3):1047-54. PubMed ID: 3510719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune inhibition of allogeneic lymphoma cells in the peritoneal cavity of mice.
    Fioretti MC; Libarati M; Bonmassar E; Cudkowicz G
    Cancer Res; 1975 Jan; 35(1):30-6. PubMed ID: 1089042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor cell destruction by cytotoxic T lymphocytes: the basis of reduced antitumor cell activity in syngeneic hosts.
    Fishelson Z; Berke G
    J Immunol; 1981 May; 126(5):2048-52. PubMed ID: 6783702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.
    Zeis M; Uharek L; Glass B; Gaska T; Gassmann W; Mueller-Ruchholtz W
    Bone Marrow Transplant; 1994 Nov; 14(5):711-5. PubMed ID: 7889004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of long-term T-lymphoid cell lines with specific cytotoxic reactivity for a syngeneic murine lymphoma.
    Eberlein TJ; Rosenstein M; Spiess PJ; Rosenberg SA
    J Natl Cancer Inst; 1982 Jul; 69(1):109-16. PubMed ID: 6980314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effector cell stimulation-inhibition of in vitro lymphoma cell DNA synthesis and correlation with in vivo antitumor response.
    Gordon WC; Prager MD
    Cancer Res; 1977 Feb; 37(2):507-13. PubMed ID: 832275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional activity in vivo of effector T cell populations. II. Anti-tumor activity exhibited by syngeneic anti-MoMULV-specific cytolytic T cell clones.
    Engers HD; Lahaye T; Sorenson GD; Glasebrook AL; Horvath C; Brunner KT
    J Immunol; 1984 Sep; 133(3):1664-70. PubMed ID: 6205090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.